Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Urine protein marker for diagnosing myeloblastoma and application thereof

A medulloblastoma, urine protein technology, applied in the field of clinical diagnosis, can solve the problem of no urine proteome or biomarker report

Pending Publication Date: 2021-12-07
BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although, there are many proteomic studies on urine, there are no reports on the urine proteome or biomarkers associated with childhood medulloblastoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Urine protein marker for diagnosing myeloblastoma and application thereof
  • Urine protein marker for diagnosing myeloblastoma and application thereof
  • Urine protein marker for diagnosing myeloblastoma and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1. Collection and preparation of urine samples for mass spectrometry detection

[0051] 1. Enrolled patients and sample collection

[0052] In the biomarker discovery phase, urine was collected from nine children with medulloblastoma before and after tumor resection. These patients were all diagnosed at Beijing Tiantan Hospital Affiliated to Capital Medical University and underwent surgery there. The inclusion criteria for children were as follows: age ≤ 16 years old, postoperative pathologically confirmed medulloblastoma, and did not receive any treatment (radiotherapy and chemotherapy) before operation and during sample collection. The preoperative urine was collected before the operation, and the postoperative urine was collected 1-2 weeks after the operation. At this stage, the urine of 9 healthy children was also collected as a control group. In order to verify the results, the urine of 29 children with medulloblastoma before and after surgery, the urine...

Embodiment 2

[0070] Example 2. Urine protein profile analysis

[0071] 1. TMT (Tandem mass tag, tandem mass spectrometry tag) labeled quantitative proteomics analysis

[0072] 1.1 TMT labeling and offline liquid phase separation

[0073] 1) TMT quantitative labeling

[0074] 3 preoperative and corresponding postoperative samples, 3 healthy control samples, a total of 9 peptide samples were randomly labeled as 127N, 127C, 128N, 128C, 129N, 129C, 130N, 130C, 131. 10-plex Tandem Mass Tags (TMT) reagents were used according to the manufacturer's instructions (Thermo Fisher Scientific). The mixed samples of preoperative, postoperative and healthy control groups were labeled with 126TMT.

[0075] 2) Off-line high pH reversed-phase high-performance liquid chromatography for separation of TMT-labeled peptides

[0076] TMT-labeled samples were mixed and fractionated using a reversed-phase HPLC column (Waters, 4.6mm×250mm, Xbridge C18, 3μm). Put the sample on the chromatographic column and put ...

Embodiment 3

[0085] Example 3. Pathway analysis of differential proteins (Ingenuity Pathway Analysis, IPA)

[0086] All differentially expressed proteins were analyzed using IPA software (Ingenuity Systems, Mountain View, CA). These proteins are classified into disease-associated and function-associated categories and are profiled in biological pathways in Ingenuity and other databases. Sort by z-score and p-value, respectively.

[0087] Functional analysis of differentially expressed proteins

[0088] These 114 differential proteins were analyzed by IPA, and these differential proteins can be divided into two categories related to disease and function, such as tumor cell migration, apoptosis, central nervous system metastasis, stage III tumors, recurrent tumors, head Neck tumors and metastases suggest that these proteins may be associated with nervous system tumors. Proteins enriched on biological pathways associated with: clathrin-mediated endocytic signaling, glycolysis I, role of ti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a urine protein marker for diagnosing myeloblastoma and application of the urine protein marker. Specifically, the invention relates to application of a reagent for detecting the content of protein in urine of a subject in preparation of a reagent for diagnosis and / or prognosis of medulloblastoma of the subject, and the protein in the urine is selected from one or more of CADH1, FIBB, FGFR4, A1BG, 1433B, VSIG4, LYVE1, KVD28, GELS, PGRP1, LV321, SAP3, IGLC2, PCOC2, GGT6, OGFD3 and LIRB4.

Description

technical field [0001] The present invention relates to the technical field of clinical diagnosis. In particular, the present invention relates to urine protein markers for the diagnosis of medulloblastoma. Specifically, the present invention relates to a urine protein marker related to human, especially children's medulloblastoma obtained by mass spectrometry proteomics technology and its use. Background technique [0002] Medulloblastoma (MB) is a kind of malignant brain tumor that mostly occurs in children, accounting for about 30% of malignant brain tumors in children. The clinical progress of the tumor is rapid, and recurrence is very easy, and about 75% of children have tumor recurrence within 2 years after operation [see, A.Y.Minn, B.H. Pollock, L. Garzarella, G.V.Dahl, L.E. Kun, J.M.Ducore, A. . Shibata, J. Kepner, P.G. Fisher, Surveillance neuroimaging to detect relapse inchildhood brain tumors: a Pediatric Oncology Group study, J. Clin. Oncol. 19 (2001) 4135–4140...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68G01N33/577
CPCG01N33/57407G01N33/6848G01N33/577G01N2800/52G01N2800/60
Inventor 田永吉郝晓雷张扬李春德宫剑
Owner BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com